THE RESULTS: Amgen, the world's biggest biotech company, saw sales jump 10 percent to $4.75 billion and net income skyrocket 24 percent to $1.37 billion in the third quarter.
THE REASONS: Amgen benefited from a lower tax rate and a one-time $155 million U.S. government order for Neupogen, a drug for boosting infection-fighting white blood cells that protects against radiation exposure.
THE OUTLOOK: The company raised the lower end of its 2013 full-year profit forecast by a nickel and now expects $7.35 to $7.45 per share. Meanwhile, it's working on multiple strategies to expand its business.
- Health Care Industry